Bill Sibold, Executive Vice President and Head of Sanofi Genzyme
Bill Sibold is Executive Vice President and Head of Sanofi Genzyme, the specialty care global business unit of Sanofi.
In this role, he is a member of the Sanofi Executive Committee. Previously, Bill was the Global Head of Sanofi Genzyme’s Multiple Sclerosis, Oncology and Immunology franchises, and led the preparation for the launches of two important new immunology treatments.
Bill joined Sanofi Genzyme in 2011 as Senior Vice President and Head of Multiple Sclerosis, and oversaw the successful launches of its two MS treatments. As Head of Sanofi Genzyme, he leads the business’s efforts to maintain its leadership in rare diseases while continuing to grow in multiple sclerosis, oncology and immunology.
Bill has more than 25 years of experience in the biopharmaceutical industry since starting his career with Eli Lilly. He held a number of leadership positions at Biogen, including driving their U.S. commercial operations in neurology, oncology and rheumatology, and general management of Biogen’s Australian and Asia-Pacific business. In addition to his time with Biogen, Bill also served as Chief Commercial Officer of Avanir Pharmaceuticals.
Bill holds an MBA from Harvard Business School and a BA in Molecular Biophysics and Biochemistry from Yale University.